Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study

MLA

Côme Lepage, et al. “Lanreotide as Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumours: An International Double-Blind, Placebo-Controlled Randomised Phase II Trial – Prodige 31 REMINET: An FFCD Study.” European Journal of Cancer, vol. 175, Nov. 2022, pp. 31–40. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....741d2d1e2010a09aa7ef527afc47495e&authtype=sso&custid=ns315887.

APA

Côme Lepage, Jean-Marc Phelip, Astrid Lievre, Karine Le-Malicot, Laetitia Dahan, David Tougeron, Christos Toumpanakis, Frédéric Di-Fiore, Catherine Lombard-Bohas, Ivan Borbath, Romain Coriat, Thierry Lecomte, Rosine Guimbaud, Caroline Petorin, Jean-Louis Legoux, Pierre Michel, Jean-Yves Scoazec, Denis Smith, & Thomas Walter. (2022). Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial – Prodige 31 REMINET: An FFCD study. European Journal of Cancer, 175, 31–40.

Chicago

Côme Lepage, Jean-Marc Phelip, Astrid Lievre, Karine Le-Malicot, Laetitia Dahan, David Tougeron, Christos Toumpanakis, et al. 2022. “Lanreotide as Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumours: An International Double-Blind, Placebo-Controlled Randomised Phase II Trial – Prodige 31 REMINET: An FFCD Study.” European Journal of Cancer 175 (November): 31–40. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....741d2d1e2010a09aa7ef527afc47495e&authtype=sso&custid=ns315887.